FDA Inspection 1166545 — Baxalta US Inc.

Baxalta US Inc. — FEI 1000519965

The FDA completed an inspection of Baxalta US Inc. on April 7, 2022 in Thousand Oaks, CA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 2 citations were issued during this inspection. Product area: Biologics.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
April 7, 2022
Fiscal Year
2022
Product Type
Biologics
Project Area
Blood and Blood Products
Location
Thousand Oaks, CA (United States)

Citations

IDCFRDescription
145221 CFR 211.113(b)Validation lacking for sterile drug products
202821 CFR 211.192Extent of discrepancy, failure investigations